EGFR and neoplasm: In patients with HER2-positive tumours receiving the epidermal growth factor receptor (EGFR)/HER2 inhibitor lapatinib in an adjuvant setting, a decrease in CD44+/CD24−/low cells and tumour mammosphere-forming efficiency was observed.